Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Fatty-acid-AMP ligase FadD30 (fatty-acid-AMP synthetase) (fatty-acid-AMP synthase) | 0.0021 | 0.0021 | 0.0032 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0528 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.015 | 0.013 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.0383 | 0.6484 | 1 |
Mycobacterium ulcerans | long-chain-fatty-acid--CoA ligase | 0.0029 | 0.015 | 0.02 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.0383 | 0.6484 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0029 | 0.015 | 0.5 |
Chlamydia trachomatis | oxoacyl-ACP synthase III | 0.0383 | 0.6484 | 1 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.0383 | 0.6484 | 1 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0029 | 0.015 | 0.02 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.0383 | 0.6484 | 0.5 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.0067 | 0.083 | 1 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.0067 | 0.083 | 1 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0029 | 0.015 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.0064 | 0.0043 |
Mycobacterium ulcerans | long-chain-fatty-acid-CoA ligase | 0.0029 | 0.015 | 0.02 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0029 | 0.015 | 0.02 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0029 | 0.015 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.015 | 0.013 |
Mycobacterium tuberculosis | Probable chain -fatty-acid-CoA ligase FadD13 (fatty-acyl-CoA synthetase) | 0.0029 | 0.015 | 0.0232 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0383 | 0.6484 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0528 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0383 | 0.6484 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0528 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0029 | 0.015 | 0.5 |
Brugia malayi | AMP-binding enzyme family protein | 0.0029 | 0.015 | 0.0087 |
Schistosoma mansoni | lipoxygenase | 0.0067 | 0.083 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.015 | 0.013 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0029 | 0.015 | 0.02 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD2 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0029 | 0.015 | 0.0232 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0528 | 1 |
Mycobacterium ulcerans | fatty-acid-CoA ligase | 0.0029 | 0.015 | 0.02 |
Plasmodium vivax | multidomain scavenger receptor, putative | 0.0024 | 0.0064 | 0.0067 |
Mycobacterium ulcerans | long-chain fatty-acid CoA ligase | 0.0029 | 0.015 | 0.02 |
Loa Loa (eye worm) | hypothetical protein | 0.058 | 1 | 1 |
Brugia malayi | AMP-binding enzyme family protein | 0.0029 | 0.015 | 0.0087 |
Plasmodium falciparum | LCCL domain-containing protein | 0.0024 | 0.0064 | 0.0067 |
Onchocerca volvulus | 0.0029 | 0.015 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.0064 | 0.0043 |
Loa Loa (eye worm) | doublecortin family protein | 0.0024 | 0.0064 | 0.0043 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.0383 | 0.6484 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0029 | 0.015 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0029 | 0.015 | 0.02 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0528 | 1 |
Brugia malayi | AMP-binding enzyme family protein | 0.0029 | 0.015 | 0.0087 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.